"Rifampin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
| Descriptor ID |
D012293
|
| MeSH Number(s) |
D03.633.400.811.700 D04.345.295.750.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Rifampin".
Below are MeSH descriptors whose meaning is more specific than "Rifampin".
This graph shows the total number of publications written about "Rifampin" by people in this website by year, and whether "Rifampin" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1996 | 0 | 1 | 1 |
| 1998 | 0 | 3 | 3 |
| 1999 | 0 | 4 | 4 |
| 2000 | 2 | 1 | 3 |
| 2001 | 3 | 2 | 5 |
| 2002 | 2 | 3 | 5 |
| 2003 | 3 | 8 | 11 |
| 2004 | 5 | 3 | 8 |
| 2005 | 1 | 5 | 6 |
| 2006 | 6 | 8 | 14 |
| 2007 | 1 | 8 | 9 |
| 2008 | 4 | 3 | 7 |
| 2009 | 3 | 4 | 7 |
| 2010 | 3 | 5 | 8 |
| 2011 | 5 | 4 | 9 |
| 2012 | 4 | 5 | 9 |
| 2013 | 8 | 2 | 10 |
| 2014 | 11 | 3 | 14 |
| 2015 | 12 | 6 | 18 |
| 2016 | 9 | 7 | 16 |
| 2017 | 6 | 3 | 9 |
| 2018 | 13 | 5 | 18 |
| 2019 | 6 | 7 | 13 |
| 2020 | 8 | 5 | 13 |
| 2021 | 10 | 15 | 25 |
| 2022 | 2 | 16 | 18 |
| 2023 | 1 | 11 | 12 |
| 2024 | 6 | 6 | 12 |
| 2025 | 4 | 3 | 7 |
Below are the most recent publications written about "Rifampin" by people in Profiles.
-
Pharmacokinetics and Safety of Levofloxacin for Treatment of Rifampicin-Resistant Tuberculosis During Pregnancy and the Postpartum Period: Results from IMPAACT P1026s. Clin Pharmacokinet. 2025 Apr; 64(4):619-630.
-
Contribution of front-line, standard-of-care drugs to bactericidal responses, resistance emergence, and cure in murine models of easy- or hard-to-treat tuberculosis disease. Antimicrob Agents Chemother. 2025 May 07; 69(5):e0190124.
-
Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes. Emerg Infect Dis. 2025 Mar; 31(3):467-476.
-
Xpert MTB/RIF Ultra-resistant and MTBDRplus-susceptible rifampicin results in people with tuberculosis: utility of FluoroType MTBDR and deep sequencing. Antimicrob Agents Chemother. 2025 Mar 05; 69(3):e0167124.
-
Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis. Lancet Child Adolesc Health. 2025 02; 9(2):100-111.
-
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis. N Engl J Med. 2025 Jan 30; 392(5):468-482.
-
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial. Lancet Microbe. 2025 Feb; 6(2):100952.
-
Linezolid Pharmacokinetic-Anemia Modeling in Children With Rifampicin-Resistant Tuberculosis. Clin Infect Dis. 2024 Dec 17; 79(6):1495-1502.
-
Representativeness and adverse event reporting in late-phase clinical trials for rifampin-susceptible tuberculosis: a systematic review. Lancet Infect Dis. 2025 Feb; 25(2):e86-e98.
-
Risk-stratified treatment for drug-susceptible pulmonary tuberculosis. Nat Commun. 2024 Oct 30; 15(1):9400.